Company intelligence / Profile preview

Ribox Pharmaceuticals

Princeton, New Jersey, United Statesriboxtx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

RiboX's lead asset RXRG001 is the first-ever circular RNA therapy and is in Phase I/IIa clinical trials for radiation-induced xerostomia (RIX) and hyposalivation; early animal studies showed promising risk/benefit and the first patients have been dosed as of March 2025. No approved products yet

Therapeutic areas: ImmunologyInfectious DiseasesRare DiseasesOtherOncology
Modalities: Circular RNAOligonucleotideLarge moleculeLipid nanoparticle delivery therapy
Industry: Biotech

Partnerships

Boehringer Ingelheim Venture Fund (investor/board representation)

Beyond the preview

Go deeper on Ribox Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribox Pharmaceuticals.

Explore the full profile